{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zent CS"],"funding":["NCI NIH HHS"],"pagination":["2373-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4573786"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["56(8)"],"pubmed_abstract":["Poly-[1-6]-β-glucopyranosyl-[1-3]-β-glucopyranose (PGG) beta glucan is a Saccharomyces cerevisiae derived 1,3/1,6 glucose polymer with innate immune system activation potential. This phase I/II clinical trial enrolled 20 eligible patients with chronic lymphocytic leukemia with high-risk biological markers for early initial treatment with alemtuzumab, rituximab and PGG beta glucan (1-2-4 mg/kg/dose) over 31 days. PGG beta glucan at 4 mg/kg was well tolerated and used for the phase II study. There were three grade 3-4 toxicities at least possibly attributed to treatment. Nineteen (95%) patients responded to treatment with 13 (65%) complete responses. All patients were alive at a median follow-up of 24.4 months (range: 9.5-37). Eleven patients had progressive disease (median 17.6 months, 95% "],"journal":["Leukemia & lymphoma"],"pubmed_title":["Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates."],"pmcid":["PMC4573786"],"funding_grant_id":["CA097274","P50 CA097274"],"pubmed_authors":["Ansell SM","Zent CS","Conte MJ","Bowen DA","Weiner GJ","Witzig TE","Call TG","LaPlant BR"],"additional_accession":[]},"is_claimable":false,"name":"Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.","description":"Poly-[1-6]-β-glucopyranosyl-[1-3]-β-glucopyranose (PGG) beta glucan is a Saccharomyces cerevisiae derived 1,3/1,6 glucose polymer with innate immune system activation potential. This phase I/II clinical trial enrolled 20 eligible patients with chronic lymphocytic leukemia with high-risk biological markers for early initial treatment with alemtuzumab, rituximab and PGG beta glucan (1-2-4 mg/kg/dose) over 31 days. PGG beta glucan at 4 mg/kg was well tolerated and used for the phase II study. There were three grade 3-4 toxicities at least possibly attributed to treatment. Nineteen (95%) patients responded to treatment with 13 (65%) complete responses. All patients were alive at a median follow-up of 24.4 months (range: 9.5-37). Eleven patients had progressive disease (median 17.6 months, 95% ","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015","modification":"2025-04-18T21:49:49.84Z","creation":"2019-03-27T01:58:35Z"},"accession":"S-EPMC4573786","cross_references":{"pubmed":["25676035"],"doi":["10.3109/10428194.2015.1016932"]}}